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Abstract 17 
	18 
Antimicrobial resistant bacteria are increasingly detected from canine samples but few studies 19 
have examined commensal isolates in healthy community dogs.	We aimed to characterise faecal 20 
Escherichia	coli from 73 healthy non-veterinarian-visiting and non-antimicrobial treated 21 
Labrador retrievers, recruited from dog shows in the North West United Kingdom between 22 
November 2010 and June 2011. Each enrolled dog provided one faecal sample for our study. E.	23 
coli were isolated from 72/73 (99%) faecal samples. Disc diffusion susceptibility tests were 24 
determined for a range of antimicrobials, including phenotypic extended-spectrum beta-25 
lactamase (ESBL) and AmpC-production. PCR assay detected phylogenetic groups and 26 
resistance genes (blaCTX-M, blaSHV, blaTEM, blaOXA, blaCIT, qnr), and conjugation experiments were 27 
performed to investigate potential transfer of mobile genetic elements. Multivariable logistic 28 
regression examined potential risk factors from owner-questionnaires for the presence of 29 
antimicrobial resistant faecal E.	coli. Antimicrobial resistant, multi-drug resistant (≥ 3 30 
antimicrobial classes; MDR) and AmpC-producing E.	coli were detected in 63%, 30% and 16% of 31 
samples, respectively. ESBL-producing E.	coli were detected from only one sample and 32 
conjugation experiments found that blaCTX-M and blaCIT were transferred from commensal E.	coli 33 
to a recipient strain. Most isolates were phylogenetic groups B1 and A. Group B2 isolates were 34 
associated with lower prevalence of resistance to at least one antimicrobial (P	< 0.001) and 35 
MDR (P	< 0.001). Significant at P ≤ 0.003, was the consumption of raw meat for clavulanate-36 
amoxicillin (OR: 9.57; 95% CI: 2.0-45.7) and third generation cephalosporin resistance (3GCR) 37 
(OR: 10.9; 95% CI: 2.2-54.0). AMR E.	coli were surprisingly prevalent in this group of non-38 
antimicrobial treated and non-veterinarian-visiting dogs and consumption of raw meat was a 39 
significant risk factor for antimicrobial resistance. These findings are of concern due to the 40 
increasing popularity of raw-meat canine diets, and the potential for opportunistic infection, 41 
zoonotic transmission and transmission of antimicrobial resistant determinants from 42 
commensal isolates to potential pathogenic bacteria. 43 
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Keywords:	E.	coli, Dogs, Multi-drug resistance, ESBL, AmpC, Phylogenetic group 45 
1.	 Introduction 46 
	47 
Escherichia	coli	is the main aerobe of the gastro-intestinal flora in humans and other animals 48 
(Tenaillon et al., 2010), and has been widely studied as an indicator of antimicrobial selection 49 
pressure (Gronvold et al., 2010). A stable gastrointestinal flora is important for health and acts 50 
as a colonisation barrier against pathogens (Vollaard and Clasener, 1994; Dethlefsen et al., 51 
2007); this may be disturbed by a number of factors including disease, diet and antimicrobial 52 
therapy (Stecher and Hardt, 2008; Jernberg et al., 2010; Vincent et al., 2010).   53 
 54 
Of particular concern is the emergence and dissemination of extended spectrum beta-lactamase 55 
(ESBL) and AmpC-producing E.	coli that are resistant to a variety of beta-lactam antimicrobials 56 
including third generation cephalosporins (3GCR) (Livermore and Hawkey, 2005; Thomson, 57 
2010). Genes encoding these enzymes are carried on plasmids, often in conjunction with other 58 
antimicrobial resistance determinants, enabling horizontal transmission of multidrug resistance 59 
(MDR) (Zhao et al., 2001; Li et al., 2007; Karczmarczyk et al., 2011; Dahmen et al., 2012). ESBL-, 60 
AmpC-producing and MDR E.	coli have been detected in healthy (De Graef et al., 2004; Carattoli 61 
et al., 2005; Costa et al., 2008; Wedley et al., 2011) and sick dogs (Carattoli et al., 2005; Pomba et 62 
al., 2009; Gibson et al., 2011a), and increased detection has been associated with exposure to 63 
antimicrobials and veterinary healthcare (Moreno et al., 2008; Damborg et al., 2011; Gibson et 64 
al., 2011a, b). 65 
 66 
E.	coli populations include commensal and pathogenic strains. Compared to commensal strains, 67 
pathogenic strains are more likely to carry a range of virulence genes that can facilitate disease 68 
(Johnson and Russo, 2002; Nowrouzian et al., 2006). Gut colonisation by ExPEC (extra-intestinal 69 
pathogenic E.	coli) strains is a prerequisite for extra-intestinal infections. The gut of healthy 70 
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humans and other animals can be a reservoir of ExPEC strains (Johnson et al., 2003; Russo and 71 
Johnson, 2003), which are potentially zoonotic (Johnson et al., 2009), and may be shared 72 
between humans and pets within households (Johnson et al., 2008). Food, particularly chicken 73 
meat, is also a potential source of ExPEC strains for humans and dogs (Johnson et al., 2007; 74 
Johnson et al., 2009; Vincent et al., 2010). 75 
 76 
Phylogenetic grouping is a simple and inexpensive method to investigate the genetic 77 
background, potential pathogenicity, and antimicrobial resistance traits of E.	coli isolates (Sato 78 
et al., 2014). A PCR assay to assign E.	coli isolates to four major phylogenetic groups: A, B1, B2 79 
and D (Clermont et al., 2000) has been widely used and recently updated (Doumith et al., 2012). 80 
Additionally, the original method (Clermont et al., 2000) has been revised (Clermont et al., 81 
2013) to assign isolates to eight different phylogenetic groups: A, B1, B2, C, D, E, F and 82 
Escherichia	Clade I. Phylo-groups B2, D, E and F are more likely to be involved in extra-intestinal 83 
infections compared to A, B1 or C (Picard et al., 1999; Moissenet et al., 2010; Tenaillon et al., 84 
2010) and Clade isolates are thought to reside outside of the gut (Walk et al., 2009). 85 
 86 
The distribution of these phylo-groups amongst different hosts is not heterogeneous and may 87 
depend on characteristics such as body mass, diet and environment (Gordon and Cowling, 2003; 88 
Escobar-Paramo et al., 2004; Tenaillon et al., 2010). In healthy humans, phylo-group A generally 89 
predominates followed by B2, B1 and D, whereas in animals group B1 predominates followed 90 
by A, B2 and D (Tenaillon et al., 2010). Diversity due to host diet has also been reported with 91 
group A predominating in carnivores and omnivores, and group B1 in herbivores (Escobar-92 
Paramo et al., 2006; Baldy-Chudzik et al., 2008; Carlos et al., 2010).  93 
Antimicrobial resistance has been linked to the non-B2 phylo-groups in people, cattle, pigs and 94 
dogs (Johnson et al., 2003; Moreno et al., 2008; Johnson et al., 2009). In dogs, phylo-group D 95 
isolates are more likely to be antimicrobial resistant, including fluoroquinolone, 3GCR and MDR 96 
(Platell et al., 2011; Tamang et al., 2012; Sato et al., 2014) and group B2 are more likely to be 97 
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antimicrobial susceptible (Johnson et al., 2009; Platell et al., 2011; Sato et al., 2014). However 98 
ESBL-producing fluoroquinolone resistant and MDR ExPEC strains, that further challenge 99 
therapeutic regimes are emerging amongst human clinical isolates, and have been reported in 100 
dogs (Russo and Johnson, 2003; Johnson et al., 2009; Platell et al., 2010). 	101 
 102 
Previous studies have concentrated on clinical isolates and the effects of potential risk factors, 103 
in particular antimicrobial pressure. However, few studies have examined canine 104 
gastrointestinal E.	coli	populations under natural conditions. The aim of this study was to 105 
determine the prevalence of antimicrobial resistance and determine phylogenetic groups 106 
amongst faecal E.	coli from a group of healthy non-vet visiting and non-antimicrobial treated 107 
dogs. In addition, we aimed to examine the association of these findings with potential risk 108 
factors. 109 
 110 
2.	 Methods	111 
	112 
2.1	 Study	Population	113 
The prevalence of antimicrobial resistant faecal E.	coli in healthy non-antimicrobial treated and 114 
non-veterinarian-visiting dogs was hypothesised to be low. Simple sample size estimates to 115 
determine prevalence showed that with an expected prevalence of 5%, precision of 5% and 116 
95% confidence, 73 dogs would be required. Labrador retriever dogs were recruited from two 117 
dog shows in the North West UK between November 2010 and June 2011. One healthy dog of 118 
any age was enrolled from each household following a clinical examination. Dogs that had 119 
received topical or systemic antimicrobial therapy, had been admitted to a veterinary clinic 120 
within the last 12 months, or were determined not to be healthy were excluded. All dog owners 121 
gave written informed consent before enrolment in this study and completed a two-page 122 
questionnaire regarding potential risk factors for the carriage of antimicrobial resistant bacteria 123 
that was administered at recruitment by a veterinarian. Time to complete the questionnaire was 124 
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1-2 minutes and it was either submitted at recruitment or returned with the sample by first-125 
class post. The questionnaire had been previously used (Wedley et al., 2014) and consisted of 126 
simple closed questions with tick box responses and space for additional information. A “Don’t 127 
Know” response was included for all questions to enable the respondent to avoid answering 128 
incorrectly if they were uncertain.  129 
Data were collected regarding patient signalment and diet, the presence, number and type of in-130 
contact pets, previous medical history of the household (including antimicrobial therapy or 131 
hospitalisation of people or other pets), and whether household members worked with farm 132 
animals or in healthcare. The University of Liverpool, School of Veterinary Science Ethics-133 
Committee approved the study protocol. 134 
 135 
2.2	 	Specimen	collection	and	bacterial	isolation	136 
The next fresh faecal sample was collected in a sterile pot and submitted at enrolment or 137 
returned by first-class post. Faecal samples were mixed with an equal volume of brain heart 138 
infusion broth with 5% glycerol (BHI-G) on receipt. Each faecal homogenate was streaked onto 139 
one eosin methylene blue agar (EMBA) plate without antimicrobials, one EMBA plate 140 
impregnated with 1 μg/ml ceftazidime (CZ) and one EMBA plate impregnated with 1 μg/ml 141 
cefotaxime (CX) (Liebana et al., 2006).  In addition, one EMBA plate and one MacConkey’s agar 142 
(MAC) plate were inoculated with the faecal homogenate for confluent bacterial growth and 143 
seven antimicrobial discs [(10 μg ampicillin (Amp), 30 μg clavulanate-amoxicillin (AC), 1 μg 144 
ciprofloxacin (Cip), 30 μg chloramphenicol (Chl), 30 μg nalidixic acid (Nal), 30 μg tetracycline 145 
(Tet) and 2.5 μg trimethoprim (Tm)] were applied (Bartoloni et al., 2006). A further 500 μL of 146 
faecal homogenate was enriched in 4.5 ml of buffered peptone water and plated onto EMBA 147 
plates impregnated with CZ and CX, as above.  All plates and broths were incubated aerobically 148 
for 18 - 20 hours at 37°C. Three colonies, whose morphology resembled E.	coli, were selected 149 
from plain EMBA. One colony growing within the zone of inhibition around each antimicrobial 150 
disc on both the EMBA and MAC and/or from the CX and/or CZ plates was selected if present. 151 
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Colonies were sub-cultured onto nutrient agar and incubated aerobically for 18 - 20 hours at 152 
37°C. Gram stains and biochemical tests (catalase production, lack of oxidase, lactose 153 
fermentation, indole production and inability to use citrate as a carbon source) to confirm E.	coli	154 
were performed on fresh overnight cultures. All antimicrobial discs were obtained from MAST 155 
Group Ltd., Liverpool, UK, and the media from LabM Ltd, Bury, UK, and the CX and CZ powder 156 
from Sigma-Aldrich Company Ltd., Gillingham, UK. 157 
 158 
2.3	 Antibiotic	susceptibility	testing	159 
Antimicrobial susceptibility disc diffusion testing was performed according to British Society for 160 
Antimicrobial Chemotherapy guidelines (BSAC; Version 11.1 May 2012) (Andrews and Testing, 161 
2007) and the same panel of seven antimicrobial discs were applied. Plates were incubated 162 
aerobically at 37°C for 18 - 20 hours. E.	coli ATCC® 25922 (LGC Standards, Teddington, UK) 163 
cultured overnight on nutrient agar at 37°C was used as a control.  164 
 165 
2.4	 Screening	for	phenoptypic	AmpC‐	and	ESBL‐producing	E.	coli	166 
Isolates with beta-lactam resistance were tested for ESBL production (Extended Spectrum Beta-167 
Lactamase Set, MAST Group Ltd., Liverpool, UK) (M'Zali et al., 2000) and AmpC production 168 
(AmpC detection set, MAST Group Ltd., Liverpool, UK)  (Halstead et al., 2012). The plates were 169 
incubated aerobically at 37°C for 18 - 20 hours.  ESBL production was confirmed when the zone 170 
around the cephalosporin disc was expanded in the presence of the clavulanic acid by a 171 
minimum of 5 mm for ≥ 1 antimicrobial pairs. AmpC production was confirmed when the zone 172 
of inhibition around disc C was greater than that for discs A and B by a minimum of 5 mm. E.	coli 173 
ATCC® 25922 (LGC Standards, Teddington, UK) cultured overnight on CAB at 37°C was used as 174 
a control. All confirmed E.	coli	isolates	were stored at – 80°C in Microbank vials (Pro-Lab, 175 
Bromborough, UK) for further analysis.  176 
	177 
2.5	 Genotypic	identification	of	E.	coli	and	characterisation	of	resistance	genes	178 
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PCR assays for the uidA gene (McDaniels et al., 1996) were used to confirm E.	coli. Isolates with 179 
phenotypic ESBL or AmpC-production were tested for the presence of blaCTX-M (Batchelor et al., 180 
2005), blaSHV, blaTEM and	blaOXA (Dallenne et al., 2010). Isolates with	blaCTX-M were tested for CTX-181 
M group 1, 2 and 9 genes (Batchelor et al., 2005; Hopkins et al., 2006). Phenotypic AmpC 182 
producers were tested for blaAmpC	gene (Perez-Perez and Hanson, 2002). All isolates were tested 183 
for the presence of qnrA, qnrB or qnr	S genes (Robicsek et al., 2006). PCR assays were 184 
performed with 5 μL of bacterial DNA, 5 pmol of each primer, 4 μL of 5x FIREPol® Master Mix 185 
(12.5 mM MgCl2), 0.5 μl of FIREPol® DNA Polymerase 5 U/μl (Solis-Biodyne, Tartu, Estonia) 186 
and water to made up to a total reaction volume of 25 μL. PCR products were analysed by 187 
agarose gel (1.5%) electrophoresis and the DNA fragments were visualised under UV light after 188 
peqGREEN (Peqlab, Fareham, UK) staining.  189 
 190 
2.6	 Phylogenetic	groups	191 
E.	coli isolates were segregated into phylogenetic groups by PCR assay. In short, a multiplex PCR 192 
for phylo-groups A, B1, B2 and D (Doumith et al., 2012) and for phylo-groups A, B1, B2, D, C, E, F 193 
and Clade I (Clermont et al., 2013) were performed.  194 
 195 
2.7	 Conjugation	experiments	196 
MDR isolates, including two ESBL- and three AmpC-producing isolates, were tested for the 197 
ability to transfer antimicrobial resistance determinants as previously described (Karczmarczyk 198 
et al., 2011). Briefly, overnight cultures of the donor and recipient strains grown in 5 ml of 199 
nutrient broth were mixed and incubated at 37°C for 18 hours. The transconjugants were 200 
selected on MacConkey agar supplemented with 100 μg/ml rifampin along with 50 μg/ml 201 
ampicillin, 50 μg/ml nalidixic acid, 30 μg/ml tetracycline, 50 μg/ml trimethoprim or 1 μg/ml of 202 
cefotaxime (Sigma-Aldrich, UK). If present, up to three lactose-negative colonies were selected 203 
from each plate onto nutrient agar and incubated at 37°C for 18 hours. Transconjugates 204 
underwent antimicrobial susceptibility tests and PCR assay for blaAmpC and blaCTX-M. 205 
Page 9 of 28
Ac
ce
pte
d M
an
us
cri
pt
 9
 206 
2.8	 Statistical	analysis	207 
Outcome data for antimicrobial resistance phenotype were collapsed to the sample level such 208 
that a sample with at least one isolate that was resistant was classed as resistant for analysis.  209 
Independent variables were created from the owner questionnaires. Except for the age of the 210 
dog, all variables were dichotomous (Supplementary table 1). The six antimicrobial resistant 211 
outcomes considered were: AMR (any resistance), clavulanate-amoxicillin (ACR), ciprofloxacin 212 
(CipR), third generation cephalosporin (3GCR), beta-lactam resistance (BLR) and MDR 213 
(resistance to ≥ 3 antimicrobial classes). Each resistance outcome was a yes/no variable. 214 
Logistic regression examined the association between independent variables and all outcomes. 215 
All variables were analysed in a univariable models and tested in multivariable models if P-216 
value < 0.25.  Final models were constructed by manual backwards stepwise procedures where 217 
variables with a likelihood ratio P-value < 0.05 were retained. Prior to inclusion in the models, 218 
age was categorised and each category was confirmed for linearity of the odds ratio. Collinearity 219 
between explanatory variables was assessed using two-by-two tables and Pearson’s Chi-square 220 
test for independence (if N > 5), otherwise Fisher’s exact tests were used. For variables with a 221 
significant association (P < 0.05) only variables with the lowest P-value were considered for 222 
inclusion in the multivariable models. Sidak‐Bonferroni	(Keppel, 2004)	correction was used to 223 
calculate a corrected P-value based on testing six antimicrobial resistance outcomes; hence 224 
significance was set at P < 0.0085.  225 
 226 
To examine the agreement of the published between two published methods for determining E.	227 
coli phylogenetic groups at the isolate level (Doumith et al., 2012; Clermont et al., 2013), a kappa 228 
statistic was calculated (Landis and Koch, 1977). Confidence intervals were calculated and 229 
Fisher’s exact tests were used to examine the association between antimicrobial resistance 230 
outcome and phylogenetic group at the isolate level detected by the Doumith et al. (2012) 231 
method. The corrected P-value (calculated as above) for 24 tests was 0.002. 232 
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 233 
Tests for kappa	statistic,	Pearson’s Chi-square and binary logistic regression were performed 234 
using SPSS software package (SPSS 20.0 for Mac, SPSS Inc, Chicago, Illinois). Tests for Fisher’s 235 
exact were performed using GraphPad Software 2014 236 
(http://graphpad.com/quickcalcs/contingency1.cfm). 237 
 238 
Results	239 
	240 
3.1	 Study	population	241 
In total, 73 Labrador retriever dogs were recruited providing one sample each: 3 to 12-months-242 
old (n = 21 dogs), >12 months to 24-months-old (n = 25), and > 2-years-old (n = 25). There were 243 
35 female and 38 male dogs. Dogs were from 23 counties of England, Northern Ireland, Scotland 244 
and The Isle of Man. The largest proportion (40%) was from the northwest of England.  245 
 246 
3.2	 Antimicrobial	resistance	247 
Faecal E.	coli were isolated from 72 sampl s (99%; 95% CI: 92.6-99.8). Of these 46 samples had 248 
at least one AMR E.	coli	and 22 samples had at least one MDR isolate (Figure 1). A high 249 
prevalence of resistance to ampicillin and/or tetracycline and/or trimethoprim, and MDR was 250 
observed. Only one sample carried MDR (AmpR, 3GCR, TetR, TMR) ESBL-producing faecal E.	coli 251 
(CTX-M group 1 and blaTEM). Phenotypic AmpC-producing E.	coli (n = 16 isolates) were detected 252 
in 12 samples (16%; 95% CI: 9.7-26.6), but only three samples carried blaAmpC gene (all CIT). E.	253 
coli with blaSHV, blaOXA or qnr	genes were not detected in any sample. 254 
 255 
3.3	 Phylogenetic	groups	256 
Table 1 shows the assignment of isolates to groups B1, B2, A and D for both methods (Doumith 257 
et al., 2012; Clermont et al., 2013). Most isolates were of B1, followed by A, B2 and D 258 
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phylogenetic groups. Approximately three quarters of the isolates originally assigned to group A 259 
by the Doumith method were reassigned to either group C (n = 39) or Escherichia Clades III-IV 260 
(n = 4 isolates) by the Clermont method; nine isolates that were initially assigned to either 261 
group B1 (n = 1), B2 (n = 3) or D (n = 5) were reassigned to group E. Three isolates, assigned to 262 
group D by the Doumith method, were reassigned to group F, and two isolates originally 263 
grouped as B1 were classed as unknown by the Clermont method. The agreement between the 264 
two methods was very good for the assignment of phylo-groups B1 and B2, but only fair or 265 
moderate for phylo-groups A and D, respectively (Landis and Koch, 1977).  266 
 267 
3.1	 Conjugation	studies	268 
In total, 23 isolates transferred resistance to the recipient strain including ESBL- and AmpC-269 
producing E.	coli (Table 2).  270 
	271 
3.2	 Association	between	isolate	phylo‐group	and	antimicrobial	resistance		272 
Table 3 shows that the majority of the isolates in phylo-groups A, B1 and D were resistant to at 273 
least one antimicrobial (AMR), particularly a beta-lactam. Group B2 did not contain isolates with 274 
clavulanate-amoxicillin resistance, 3GCR or MDR and group B2 was associated with significantly 275 
lower levels of AMR and MDR (P < 0.001) compared to the other groups. Ciprofloxacin 276 
resistance was spread between the different phylo-groups.  277 
 278 
3.3	 Logistic	regression:	antimicrobial	resistance	with	questionnaire	data	279 
All of the dogs in the study were fed dry dog food; however some were supplemented with 280 
tinned dog food, home-cooked meats, proprietary dog treats, table scraps or raw meat. In 281 
addition, 42 dogs regularly scavenged from the environment. Clavulanate-amoxicillin resistance 282 
(P	= 0.003) and 3GCR (P = 0.002) were associated with dogs eating raw meat (chicken, red-meat 283 
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and/or tripe), whilst consumption of proprietary dog treats appeared to be protective against 284 
ciprofloxacin (P = 0.003) and MDR (P = 0.001) E.	coli	(Table 4).  285 
 286 
3.	 Discussion	287 
	288 
This study found an unexpected high prevalence of AMR (including MDR and phenotypic AmpC-289 
producers), amongst canine faecal E.	coli from a group of healthy Labrador retrievers in the UK, 290 
in the absence of direct antimicrobial selective pressure and veterinary premises contact.   291 
 292 
The prevalence of MDR in this study was 30% of dogs (95% CI: 19.6 – 40.6). A previous healthy 293 
dog study In North West UK reported a MDR prevalence of 15.3% of dogs (95% CI: 10.4-20.5) 294 
(Wedley et al., 2011). This variation may be due to the five-year difference in sample collection 295 
between the studies; prevalence of AMR may have increased in such populations over time, or it 296 
may be due to differences in the sampled populations. The dogs in this study were regularly in 297 
close contact, in confined spaces, with many other dogs and humans at dog shows all over the 298 
UK. Sharing of faecal E.	coli isolates may occur between dogs and between dogs and humans in 299 
regular close proximity, including MDR resistant strains (Skurnik et al., 2006; Johnson et al., 300 
2008; Damborg et al., 2009; Stenske et al., 2009; Harada et al., 2011), and dogs housed together 301 
in groups may have a higher prevalence of AMR faecal E.	coli than individual dogs (De Graef et 302 
al., 2004).   303 
 304 
Only 5% of the dogs in this study had 3GCR faecal E.	coli with either blaCTX-M (1 dog) or blaAmpC 305 
(three of the 12 dogs with phenotypic AmpC production), in agreement a low prevalence (4%) 306 
of healthy dogs with faecal E.	coli harbouring these genes has previously been reported in the 307 
UK (Wedley et al., 2011). Antimicrobial therapy with enrofloxacin or cefalexin has been 308 
reported to select for faecal E.	coli carrying blaCTX-M or blaAmpC (Moreno et al., 2008; Damborg et 309 
al., 2011) and the absence of antimicrobial therapy of dogs in the current study may explain the 310 
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low prevalence. Ciprofloxacin resistance was uncommon, but when present corresponded with 311 
MDR. This finding has been previously reported amongst canine clinical isolates, where it was 312 
proposed that this was due to ‘last-line’ clinical use of fluoroquinolones in dogs (Platell et al., 313 
2011). 314 
 315 
Group B1 was the most common phylo-group detected, followed by A, B2 and D, which concurs 316 
with Tenaillon et al. (2010) who reviewed a number publications examining faecal E.	coli from 317 
various animal species. Damborg et al. (2009) also reported a predominance of phylo-group B1 318 
in dogs (n = 13). However, in other studies a predominance of group B1 followed by group A has 319 
been reported in farmed and wild herbivorous animals (Escobar-Paramo et al., 2006; Carlos et 320 
al., 2010), whereas omnivorous and carnivorous animals had a predominance of A followed by 321 
B1 (Escobar-Paramo et al., 2006). The base diet of the dogs in this study was proprietary dry 322 
dog food, consisting of a combination of crude fibre and protein, equivalent to an omnivorous 323 
diet. Hence, we expected the phylogenic diversity to be similar to that reported for other 324 
domesticated omnivorous animals. High levels of crude dietary fibre found in some dog foods 325 
could impact the abundance of certain phylo-groups, for example decrease cell densities of B2 326 
strains compared to B1 strains (O'Brien and Gordon, 2011), although this variable was not 327 
examined in the current study. Phylo-group B1 predominate in soil, sediment and water, the 328 
secondary habitat of E.	coli (Savageau, 1983; Walk et al., 2007), representing a potential source 329 
for dogs that frequently drink, scavenge and/or orally explore their environments.  330 
	331 
Previous studies have reported that antimicrobial resistant E.	coli from humans and dogs are 332 
less likely to be of phylo-group B2 (Johnson et al., 2003; Johnson et al., 2009; Platell et al., 2010; 333 
Platell et al., 2011; Sato et al., 2014). Similarly in this study, group B2 isolates were less likely to 334 
be antimicrobial resistant and there were no MDR, 3GCR or clavulanate-amoxicillin resistant 335 
isolates in this group. The majority of the phylo-group D isolates were resistant to at least one 336 
tested antimicrobial however this was not found to be statistically significant. Other studies 337 
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have reported a relationship between group D and fluoroquinolone resistance, 3GCR and MDR 338 
(Deschamps et al., 2009; Platell et al., 2011; Tamang et al., 2012; Sato et al., 2014). These 339 
associations were not made in this study, although this may have been affected by the low 340 
prevalence of these resistance outcomes in phylo-group D, in particular fluoroquinolone 341 
resistance.   342 
 343 
There was very good agreement between the two methods for assigning isolates to groups B1 344 
and B2 but only fair to moderate for groups A and D respectively.  This was due to reassignment 345 
of group A strains to group C, and group D strains to groups B1, E and F. Other studies have 346 
compared multiplex PCR and MLST for phylogenetic grouping and reported 80-90% accuracy 347 
for the multiplex method; mostly due to agreement for groups B1 and B2 rather than A and D 348 
(Gordon et al 2008; Doumith et al 2012). Further comparison of the new Clermont multiplex 349 
PCR method with MLST for phylo-grouping may find improved accuracy for assignment of 350 
groups A and D. The new Clermont method for assigning phylogenetic groups classed 39 351 
isolates as group C. Compared to commensal E.	coli from other species (human, bird, non-human 352 
mammals) (Clermont et al., 2013) this phylo-group appears to be prevalent in this group of 353 
dogs, but further studies are required to confirm this finding. Phylo-groups E and F are potential 354 
ExPEC strains (Tenaillon et al., 2010) and were re-assigned from the other potential ExPEC 355 
groups, D and B2.   356 
 357 
Multivariable analysis found a relationship between consumption of raw meat diets (chicken, 358 
red meat and/or tripe) and resistance to clavulanate amoxicillin or 3GCR. In contrast, 359 
consumption of proprietary dog treats appeared to be protective against ciprofloxacin 360 
resistance and MDR. Food, particularly chicken meat, has been reported as a possible source of 361 
antimicrobial resistant bacteria, including ExPEC, for humans and dogs (Johnson et al., 2007; 362 
Lefebvre et al., 2008; Johnson et al., 2009; Vincent et al., 2010). Both ESBL- and AmpC-363 
producing, and ciprofloxacin resistant E.	coli have been isolated from chickens and pigs in Spain, 364 
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and the predominant phylo-groups reported from chickens, pigs and cattle in the US, Spain and 365 
South Korea are B1, A and D (Johnson et al., 2003; Johnson et al., 2007; Unno et al., 2009; Cortes 366 
et al., 2010). Recommendations to feed raw meat diets are of some concern, as raw meats may 367 
be a source of AMR and/or pathogenic organisms that are potential animal and a public health 368 
risks and this needs further investigation (Johnson et al., 2008). 369 
 370 
It is likely that the canine faecal flora consists of a variety of organisms in addition to canine 371 
resident bacteria, derived from in contact humans and animals, diet or the environment. Newly 372 
introduced bacteria may act as a reservoir of antimicrobial resistant determinants for resident 373 
bacteria even if only transient in the gut and selective pressure through antimicrobial therapy 374 
may facilitate establishment as permanent residents of the gut flora.  375 
 376 
Limitations of this study include the low number of observations for some outcomes, which 377 
reduced the power of the study. Selection and testing of more isolates may have increased the 378 
detection of antimicrobial resistance, in particular ESBL-producing E.	coli. However, despite the 379 
small subgroups, we were able to identify strong associations between outcomes and risk 380 
factors. It is possible that some isolates were not detected due to postal delivery and delayed 381 
processing. However (Maule, 2000) reported E.	coli	survival in aerated manure of at least a 382 
month. Another limitation was that the study only included one dog breed and was in a limited 383 
demographic area. It is possible that samples from other breeds and other geographical 384 
populations would differ.  385 
 386 
4.	 Conclusion	387 
 388 
In conclusion, the overall prevalence of AMR and MDR amongst canine faecal E.	coli	was higher 389 
than expected for a group of healthy non-veterinarian-visiting and non- antimicrobial-treated 390 
dogs. The predominant faecal E.	coli phylogenetic group in these dogs was group B1, and group 391 
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B2 isolates were less likely than the other groups to harbour antimicrobial resistance, in 392 
agreement with previous work. In particular, consumption of raw meat diets were associated 393 
with increased detection of 3GCR and clavulanate-amoxicillin resistant canine faecal E.	coli in 394 
this group of dogs, representing a potential animal welfare and zoonotic risk.  395 
 396 
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Table	1.	Cross tabulation of the results of E.	coli isolates, from 74 dogs recruited from UK dog 617 
shows between November 2010 and June 2011, classified as phylogenetic groups A, B1, B2 or D 618 
by both Doumith et al 2012 and Clermont et al 2013 Multiplex PCR methods. 619 
	620 
Table	2.	Conjugation	experiments:	resistance	phenotype	and	genes	detected	in	25	donor	621 
E.	coli	isolates,	from	73	dogs	recruited	from	UK	dog	shows	between	November	2010	and	622 
June	2011,	and	transconjugates.		623 
The recipient strain was rifampin-resistant, lactose-negative E.	coli 26R793. AMP = ampicillin; 624 
AC = clavulanate-amoxicillin; CIP = ciprofloxacin; CHL = chloramphenicol; NAL = nalidixic acid; 625 
TET = tetracycline; TM = trimethoprim; 1present in donor and transconjugate. 626 
 627 
Table	3.	Cross	tabulation	of	the	186	E.	coli	isolates,	from	74	dogs	recruited	from	UK	dog	628 
shows	between	November	2010	and	June	2011,	in	each	of	four	phylogenetic	group	and	629 
each	of	six	antimicrobial	resistance	outcomes.	630 
ACR = clavulanate-amoxicillin resistance, CipR = ciprofloxacin resistance; BLR = beta-lactam 631 
resistance; 3GCR = third generation cephalosporin resistance, AMR = any antimicrobial 632 
resistance, MDR = resistance to ≥ 3 antimicrobial classes; n = total number of isolates in each 633 
phylogenetic group with each antimicrobial resistance outcome; % = percentage of isolates in 634 
each phylogenetic group with each antimicrobial resistance outcome; CI = 95% confidence 635 
interval; P	= P-value is from Fisher’s exact test (two-tailed); Significant set at P < 0.002 (Sidak‐636 
Bonferroni	correction). 637 
 638 
Table	4.	Final	multivariable	logistic	regression	models	for	clavulanate‐amoxicillin	639 
resistance,	ciprofloxacin	resistance,	3GCR	and	MDR	outcomes	for	faecal	E.	coli	in	73	640 
samples	from	73	dogs	recruited	from	dog	shows	in	the	UK	between	November	2010	and	641 
June	2011.	642 
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1 Reference category is the absence of the risk factor; 2Within 12 months of enrolment; 3GCR = 643 
3rd generation cephalosporin resistance; MDR = antimicrobial resistance to three or more 644 
antimicrobial classes; 3Hosmer and Lemeshow Goodness-of-fit; P-value; Covariate P values are 645 
from the * Likelihood-ratio test statistic. Significant set at P < 0.0085 (Sidak‐Bonferroni	646 
correction). 647 
	648 
Figure	1.	The	percentage	of	73	samples	with	at	least	one	faecal	E.	coli	with	resistance	to	649 
the	tested	antimicrobials	for	73	dogs	(95%	CI)	recruited	from	UK	dogs	shows	between	650 
November	2010	and	June	2011.		651 
AmpR = ampicillin resistance; ACR = clavulanate-amoxicillin resistance; CipR = ciprofloxacin 652 
resistance; NalR = nalidixic acid resistance; ChlR = chloramphenicol resistance; TetR = 653 
tetracycline resistance; TmR = trimethoprim resistance; 3GCR = third generation cephalosporin 654 
resistance; BLR = beta-lactam resistance; AMR = resistance to at least one tested antimicrobial; 655 
MDR = multidrug resistance (resistance to three or more antimicrobial classes) 656 
 657 
 658 
659 
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Table 1. Cross tabulation of the results of E.	coli isolates, from 73 dogs recruited from UK dog 659 
shows between November 2010 and June 2011, classified as phylogenetic groups A, B1, B2 or D 660 
by both Doumith et al 2012 and Clermont et al 2013 Multiplex PCR methods. 661 
Clermont A 
 No Yes Total 
No Number of isolates 128 2 130Doumith A 
Yes Number of isolates 43 14 57
Number of isolates 171 16	 187Total 
Kappa	= 0.29; SE: 0.07, P < 0.001
 662 
Clermont B1 
 No Yes Total 
No Number of isolates 105 4 109Doumith B1 
Yes Number of isolates 5 73 78
Number of isolates 110 77	 187Total 
Kappa	= 0.9; SE: 0.03, P < 0.001
 663 
Clermont B2 
 No Yes Total 
No Number of isolates 154 2 156Doumith B2 
Yes Number of isolates 3 28 31
Total number of isolates 157 31	 187 
Kappa	= 0.9; SE: 0.043, P < 0.001
 664 
Clermont D 
 No Yes Total 
No Number of isolates 167 0 167Doumith D 
Yes Number of isolates 13 7 20
 Number of isolates 180 7	 187Total 
Kappa	= 0.49; SE: 0.12, P < 0.001
 665 
 666 
 667 
 668 
669 
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Table	2.	Conjugation	experiments:	resistance	phenotype	and	genes	detected	in	25	donor	669 
E.	coli	isolates,	from	73	dogs	recruited	from	UK	dog	shows	between	November	2010	and	670 
June	2011,	and	transconjugates.		671 
Donor	resistance	phenotype	 Transconjugate	resistance	phenotype	 blaCIT or	blaCTX-M		gene1		
AMP, TET, TM AMP, TET, TM  
AMP, CHL, TET, TM AMP, TET, TM  
AMP, CHL, TET, TM AMP, CHL, TET, TM  
AMP, TET, TM TET  
AMP, CHL, TET, TM AMP, TET  
AMP, TET, TM AMP, TET, TM  
AMP, TET, TM AMP, TET, TM  
AMP, CIP, TET, TM AMP, TET, TM  
AMP, AC, CIP, CHL, NAL, TET, TM AMP blaCIT 
AMP, CHL, TET AMP, CHL, TET  
AMP, CHL, TET AMP, CHL, TET  
AMP, CHL, NAL, TET, TM AMP, TET, TM  
AMP, CIP, CHL, NAL, TET, TM AMP, CHL, TET, TM  
AMP, CHL, TET AMP, CHL, TET  
AMP, TET, TM AMP, TET, TM  
AMP, AUG, CHL, TM AMP, TM  
AMP, CHL, TET, TM AMP  
AMP, CIP, CHL, NAL, TET, TM AMP, CHL, TET, TM  
AMP, CHL, TET AMP, CHL, TET  
AMP, CHL, TET AMP, CHL, TET  
AMP, CHL, TET AMP, CHL, TET  
AMP, CHL, TET AMP, CHL, TET  
AMP, CHL, TET AMP, CHL, TET  
AMP, CIP, CHL, NAL, TET, TM AMP, CHL, TET, TM  
AMP, TET, TM AMP, TET, TM blaCTX-M 
The recipient strain was rifampin-resistant, lactose-negative E.	coli 26R793. AMP = ampicillin; 672 
AC = clavulanate-amoxicillin; CIP = ciprofloxacin; CHL = chloramphenicol; NAL = nalidixic acid; 673 
TET = tetracycline; TM = trimethoprim; 1present in donor and transconjugate. 674 
 675 
676 
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 676 
Phylogenetic	group	
A	(n	=	57)	 B1	(n	=	78)	 B2	(n	=	31)	 D	(n	=	20)	
Resistance	
Outcome	
 n	 %	 CI	 P	 n	 %	 CI	 P	 n	 %	 CI	 P	 n	 %	 CI	 P	
ACR	(n	=	24)	 6 11 2.6 -
18.5 
0.6 11 14 6.4 – 
21.8 
0.7 0 0 0 0.016 7 35 14 – 
55.9 
0.006 
CipR	(n	=	19)	 8 14 5.0 – 
23.0 
0.3 8 10 3.5 – 
17.0 
0.9 2 6 0 - 15 0.75 1 5 0 – 
14.6 
0.7 
BLR	(n	=	109)	 35 61 48.8 – 
74.0 
0.6 48 62 50.7 – 
72.3 
0.5 12 39 21.6 – 
55.9 
0.027 15 75 56 – 
94.0 
0.15 
3GCR		(n	=	19)	 5 9 1.4 – 
16.1 
0.8 8 10 3.5 – 
17.0 
0.9 0 0 0 0.4 6 30 9.9 
– 
50.1 
0.008 
AMR	(n	=	148)	 49 86 76.9 – 
95.0 
0.2 65 83 75.1 – 
91.6 
0.3 17 55 37.3 – 
72.4 
< 
0.001 
19 95 85.5 
– 
100 
0.08 
MDR	(n	=	61)	 24 42 29.3 – 
54.9 
0.09 31 40 8.9 – 
50.6 
0.08 0 0 0 < 
0.001 
6 30 9.9 
– 
50.1 
0.99 
ACR = clavulanate-amoxicillin resistance, CipR = ciprofloxacin resistance; BLR = beta-677 
lactam resistance; 3GCR = third generation cephalosporin resistance, AMR = any 678 
antimicrobial resistance, MDR = resistance to ≥ 3 antimicrobial classes; n = total number 679 
of isolates in each phylogenetic group with each antimicrobial resistance outcome; % = 680 
percentage of isolates in each phylogenetic group with each antimicrobial resistance 681 
outcome; CI = 95% confidence interval; P	= P-value is from Fisher’s exact test (two-682 
tailed); Significant set at P < 0.002 (Sidak‐Bonferroni	correction). 683 
 684 
685 
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Table	4.	Final	multivariable	logistic	regression	models	for	clavulanate‐amoxicillin	685 
resistance,	ciprofloxacin	resistance,	3GCR	and	MDR	outcomes	for	faecal	E.	coli	in	73	686 
samples	from	73	dogs	recruited	from	dog	shows	in	the	UK	between	November	2010	and	687 
June	2011.	688 
Resistance	outcome	
 
Covariates	 B	 SE	(b)	 Adjusted	OR	 95%	CI	 P‐value*	
Clavulanate‐amoxicillin	 	 	 	 	 	 	
P = 0.83 Dog eats raw meat1 2.3 0.8 9.57	 2.0 - 45.7 0.003 
 In-contact had antimicrobials2 -1.6 0.8 0.19 0.04 - 0.9 0.028 
 Constant -1.5 0.5   0.005 
Ciprofloxacin	 	 	 	 	 	 	
P = 0.99 3 Dog fed treats1 -1.9 0.8 0.1	 0.03 - 0.6 0.007 
 Dog eats raw meat1 0.9 0.8 2.6	 0.5-12.2 0.25 
 Constant -0.6 0.5   0.19 
3GCR		 	 	 	 	 	 	
P = 0.9 3 Dog eats raw meat1 2.4 0.8 10.9	 2.2 – 54.0 0.002 
 In contact had antimicrobials1 -1.6 0.8 0.2 0.04 - 0.9 0.05 
 Multi-animal household1 1.6 0.9 5.1 1.0 - 26.5 0.04 
 Constant -2.4 0.7   0.001 
MDR	 	 	 	 	 	 	
P = 0.5 3 Dogs fed treats1 -1.9 0.6 0.16	 0.04 - 0.5 0.001 
 Owner works with farm animals1 -1.5 0.9 0.2 0.04 - 1.3 0.07 
 Constant 0.7 0.5   0.16 
1 Reference category is the absence of the risk factor; 2Within 12 months of enrolment; 3GCR = 689 
3rd generation cephalosporin resistance; MDR = antimicrobial resistance to three or more 690 
antimicrobial classes; 3Hosmer and Lemeshow Goodness-of-fit; P-value; Covariate P values are 691 
from the * Likelihood-ratio test statistic. Significant set at P < 0.0085 (Sidak‐Bonferroni	692 
correction). 693 
 694 
 695 
 696 
697 
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 697 698 
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Highlights 698 
 699 
• Antimicrobial and multi-drug resistance was common 700 
• ESBL and plasmid-mediated AmpC-producing E.	coli were uncommon. 701 
• Most isolates were phylo-group B1; often antimicrobial resistant 702 
• Phylo-group B2 isolates were more likely to be susceptible. 703 
• The main risk for antimicrobial resistance was eating raw meat. 704 
 705 
